세계의 시신경 질환 치료 시장 규모 : 치료 유형별, 신경질환 유형별, 최종사용자별, 지역 범위별 및 예측
Global Optic Nerve Disorders Treatment Market Size By Type of Treatment (Eye Drops, Steroids), By Type of Nerve Disorder (Glaucoma, Optic neuritis), By End User (Hospitals, Ophthalmology Clinics), By Geographic Scope And Forecast
상품코드:1736743
리서치사:Verified Market Research
발행일:2025년 05월
페이지 정보:영문 202 Pages
라이선스 & 가격 (부가세 별도)
한글목차
시신경 질환 치료 시장 규모 및 예측
시신경 질환 치료 시장 규모는 2024년 36억 달러로 평가되었고, 2026-2032년의 예측 기간 동안 연평균 4.7% 성장하여 2032년에는 57억 달러에 달할 것으로 예측됩니다.
시신경질환은 시각 정보를 눈에서 뇌로 전달하는 신경섬유군인 시신경이 염증(부종)으로 인해 파괴된 상태입니다. 시신경 질환은 한쪽 눈의 일시적인 시력 저하와 안구 운동 시 불편함을 특징으로 합니다. 시신경 질환의 유병률 증가, 좌식 생활습관, 당뇨병, 혈압 및 고혈압과 같은 생활습관병의 유병률 증가로 인해 세계의 시신경 질환 치료 시장은 예측 기간 동안 성장할 것으로 예측됩니다. 이 보고서는 세계의 시신경 질환 치료 시장을 종합적으로 평가했습니다.
세계의 시신경 질환 치료 시장 정의
망막세포와 시교차를 연결하는 뇌신경은 시신경으로 알려져 있습니다. 망막의 시세포는 빛을 받아들이고 시신경을 통해 뇌에 전기 자극을 보냅니다. 시력 상실은 병변의 유형과 부위에 따라 시신경의 기능 장애나 손상으로 인해 발생할 수 있습니다. 한쪽 눈 또는 양쪽 눈에 시력 질환이 발생할 수 있습니다. 전기 신호는 망막의 시세포에서 시신경을 통해 뇌의 시각 영역으로 전달됩니다.
시신경과 그 경로에 손상이 생기면 눈에 영구적인 손상을 입혀 시력 저하를 유발할 수 있습니다. 시신경을 손상시킬 수 있는 가장 흔한 질환 중 하나는 시신경 질환입니다. 시신경은 시신경을 덮고 있는 보호막인 미엘린의 손상이나 손실로 인해 염증을 일으킵니다. 연구자들에 따르면, 시신경 질환은 염증과 미엘린의 파괴로 인해 발생할 수 있으며, 두 신경은 시신경 교차점에서 수렴하는 중요한 역할을 합니다.
시신경이 두 동강이 나면 좌우 신경 섬유의 절반씩 반대편으로 넘어갑니다. 부상과 신경의 보호 피복의 제거는 모두 신경의 염증을 유발합니다. 시신경 질환에는 녹내장, 시신경 질환, 시신경 위축, 시신경원반돌출증(ODD) 등이 있습니다. 치료 방법으로는 코르티코스테로이드, 정맥 내 면역글로불린 주입(IVIG)/혈장교환술, 비타민 B12 주사, 수술 등이 있으며, 질환의 정도와 유형에 따라 치료 방법이 달라집니다.
세계의 시신경 질환 치료 시장 개요
세계보건기구(WHO)에 따르면 2019년 전 세계 22억 명이 시각 질환 또는 실명을 경험했습니다. 이 중 백내장, 미교정 굴절이상, 녹내장, 각막혼탁 등이 시력 질환의 주요 원인입니다. 안구 내 액압이 상승하여 시신경 질환을 악화시키는 중요한 요인 중 하나가 녹내장입니다. 녹내장은 감염이나 화학물질에 의한 안질환 등에 의해서도 발병하지만, 유전되는 경우가 많은 질환입니다. 조기 발견 및 조기 치료에는 점안약, 내복약, 레이저 치료 등의 방법이 있습니다.
다발성 경화증(MS)은 면역체계가 신체의 건강한 세포를 공격하는 자가면역질환으로 시신경 질환의 주요 원인입니다. 면역력 저하로 인해 MS는 고령화 사회에서 많이 볼 수 있으며, 당뇨병, 흡연, 감염 등에 의해서도 발병할 수 있습니다. 좌식생활, 잘못된 식습관, 운동부족 등으로 인해 당뇨병, 혈압, 고혈압 등의 생활습관병이 증가하고 있어 다발성경화증이 안구신경염을 유발할 가능성이 더욱 높아지고 있습니다. 그 결과, 이 질환에 대한 치료가 필요한 사람의 비율이 증가하고 있습니다. 시신경 질환의 치료에는 일반적으로 스테로이드가 사용되어 증상의 진행을 막는다.
시신경 질환에 대한 확실한 치료법은 없지만, 약물요법이나 투약, 수술로 인한 합병증을 피하기 위해 예방과 조기발견이 중요시되고 있습니다. 노인 인구 증가와 증상 악화를 막기 위한 조기 진단의 필요성에 대한 인식이 높아지면서 시신경 질환의 치료 및 수술에 대한 수요가 증가하고 있으며, 이러한 치료 시장의 성장을 견인하고 있습니다. 그러나 녹내장과 같은 시신경 질환 치료의 사용에 따른 잠재적인 부작용(눈 색깔 변화, 눈꼽, 가려움증 등)이 시장 확대를 저해하는 요인으로 작용하고 있습니다.
목차
제1장 세계의 시신경 질환 치료 시장 서론
시장 개요
조사 범위
전제조건
제2장 VERIFIED MARKET RESEARCH의 조사 방법
데이터 마이닝
2차 조사
1차 조사
전문가 어드바이스
품질 체크
최종 리뷰
데이터 삼각측량
보텀업 접근
톱다운 접근
조사 흐름
데이터 소스
제3장 주요 요약
개요
절대적 매출 기회
시장의 매력
향후 시장 기회
제4장 세계의 시신경 질환 치료 시장 전망
개요
시장 역학
성장 촉진요인
성장 억제요인
기회
Porter's Five Forces 모델
밸류체인 분석
제5장 세계의 시신경 질환 치료 시장 : 치료 유형별
개요
점안약
스테로이드
면역글로불린 정주/혈장 교환
비타민 B12 주사
외과 수술
제6장 세계의 시신경 질환 치료 시장 : 신경질환 유형별
개요
녹내장
시신경 질환
기타
제7장 세계의 시신경 질환 치료 시장 : 최종사용자별
개요
병원
안과 클리닉
외래수술센터(ASC)
제8장 세계의 시신경 질환 치료 시장 : 지역별
개요
북미
미국
캐나다
멕시코
유럽
독일
영국
프랑스
기타 유럽
아시아태평양
중국
일본
인도
기타 아시아태평양
기타
라틴아메리카
중동 및 아프리카
제9장 세계의 시신경 질환 치료 시장 경쟁 구도
개요
기업의 시장 순위
주요 개발 전략
기업의 지역별 실적
기업 산업별 실적
ACE 매트릭스
제10장 기업 개요
Bionure Farma S.L.
Teva Pharmaceutical Industries
Santen Pharmaceutical
Novartis AG
Pfizer
Allergan
Aerie Pharmaceuticals
Mallinckrodt Pharmaceuticals
Merck Sharp & Dohme Corp
Bausch Health Companies
제11장 주요 개발
제품 출시 및 개발
인수합병(M&A)
사업 확대
파트너십과 제휴
제12장 부록
관련 조사
LSH
영문 목차
영문목차
Optic Nerve Disorders Treatment Market Size And Forecast
Optic Nerve Disorders Treatment Market size was valued at USD 3.6 Billion in 2024 and is projected to reach USD 5.7 Billion by 2032, growing at a CAGR of 4.7% during the forecast period 2026-2032.
Optic neuritis is a condition in which the optic nerve, a group of nerve fibers that transmits visual information from the eye to the brain, is destroyed by inflammation (swelling). Optic neuritis is characterized by temporary vision loss in one eye and discomfort with eye movement. Due to the rising prevalence of optic illnesses, the adoption of a sedentary lifestyle, and the rising incidence of lifestyle diseases like diabetes, Blood Pressure & Hypertension, the global market for treatments for optic nerve disorders is anticipated to grow over the course of the forecasted period. The market is comprehensively evaluated in the study on the global market for treating optic nerve disorders.
Global Optic Nerve Disorders Treatment Market Definition
The cranial nerves that connect the retinal cells to the optic chiasm are known as the optic nerves. The retina's photoreceptor cells take in light and send electric impulses to the brain through the optic nerves. Loss of vision could result from malfunction or damage to the optic nerves, depending on the type and location of the lesion. One or both eyes could experience vision impairment. Electrical signals are sent from retinal photoreceptor cells via the optic nerve to the brain's visual cortex.
Any damage to the optic nerve or its pathways has the potential to permanently harm the eyes and cause vision loss. One of the most frequent conditions that might harm the optic nerve is optic neuritis. The optic nerve is inflamed as a result of damage to or loss of myelin, the protective covering that covers it. Optic neuritis may be brought on by inflammation and myelin breakdown, according to researchers. The two nerves perform an essential task and converge at the optic chiasm.
Half of each side's nerve fibers cross over to the other side as the optic nerve splits in half. Injury and the removal of the nerve's protective covering both cause inflammation of the nerve. Glaucoma, optic neuritis, atrophy of the optic nerve, and optic disc drusen (ODD), among other conditions, are optic nerve disorders. Therapy options include corticosteroids, intravenous immune globulin (IVIG)/plasma exchange, vitamin B12 injection, and surgery, among others, depending on the degree and kind of disease identified.
Global Optic Nerve Disorders Treatment Market Overview
In 2019, 2.2 billion individuals worldwide experienced visual impairment or blindness, according to WHO. Out of these, cataracts, uncorrected refractive errors, glaucoma, corneal opacification, etc. are the main causes of vision impairment. One significant factor that contributes to the increase in fluid pressure in the eye, which worsens optic nerve damage, is glaucoma. It is frequently inherited by people, although it can also be brought on by an infection, an eye injury from chemicals, etc. Early detection and treatment options include eye drops, oral drugs, and operations like laser therapy.
Multiple sclerosis (MS), an autoimmune condition associated with the immune system attacking the body's healthy cells, is the primary cause of optic neuritis. Due to lowered immunity, MS is becoming more common in the aging population, while it can also be brought on by diabetes, smoking, infections, etc. Due to sedentary lifestyles, bad diets, lack of physical activity, etc., there is an increase in lifestyle disorders like diabetes, blood pressure, hypertension, etc., which further increases the likelihood that MS may cause ocular neuritis. The percentage of persons who need therapy for the disease is increasing as a result. Steroids are typically used to treat optic neuritis in order to prevent the condition's future progression.
Although there is no definitive cure for optic nerve illnesses, there is a lot of emphasis on preventing them and finding them early to avoid complications from medication, medications, and surgery. The increase in the elderly population and the growing awareness of the need for early diagnosis to stop the condition from getting worse has increased the demand for drugs and surgeries for treating optic nerve disorders, which has fueled the growth of the market for those treatments. However, the market's expansion is being hampered by potential side effects associated with the usage of medications for the treatment of optic nerve disorders like glaucoma, such as changing eye color, sunken eyes, itching, etc.
Global Optic Nerve Disorders Treatment Market Segmentation Analysis
The Global Optic Nerve Disorders Treatment Market is segmented on the basis of Type of Treatment, Type of Nerve Disorder, End User, And Geography.
Optic Nerve Disorders Treatment Market, By Type of Treatment
Eye Drops
Steroids
Intravenous immune Globulin/ Plasma Exchange
Vitamin B12 injection
Surgery
Based on Type of Treatment, The market is segmented into Eye Drops, Steroids, Intravenous immune globulin (IVIG)/Plasma Exchange, Vitamin B12 injection, and Surgery. Due to their simplicity of use, quick start of the action, and increased efficacy, eye drops are predicted to experience the largest growth during the estimated period.
Numerous common disorders are treated using eye drops. They can be used for tired, itchy eyes brought on by allergies. They might be recommended for bacterial or viral infections as well as other disorders like glaucoma. The entire therapeutic benefit of the drug might not be experienced when eye drops are not properly administered or used.
Optic Nerve Disorders Treatment Market, By Type of Nerve Disorder
Glaucoma
Optic neuritis
Others
Based on Type of Nerve Disorder, The market is segmented into Glaucoma, Optic neuritis, and Others. Due to a lack of knowledge about glaucoma and the rising elderly population, glaucoma is anticipated to rise the most during the anticipated time. due to an increase in open-angle glaucoma prevalence. Additionally, it is projected that an increase in the number of medications approved for the treatment of open-angle glaucoma will spur market expansion.
Additionally, the market for treatments for optic neuritis is anticipated to increase at the quickest rate throughout the anticipated period. This is ascribed to the rise in optic neuritis prevalence, the availability of reimbursement policies, and rising public awareness of multiple sclerosis driving the market expansion.
Optic Nerve Disorders Treatment Market, By End User
Hospitals
Ophthalmology Clinics
Ambulatory Surgical Centers
Based on End User, The market is segmented into Hospitals, Ophthalmology Clinics, and Ambulatory Surgical Centers. Due to the increased prevalence of optical disorders, accessibility to cutting-edge technology, and well-established healthcare infrastructure, the hospital segment is anticipated to grow the most throughout the anticipated period.
The availability of enhanced healthcare infrastructure, the rise in unmet healthcare needs, the rise in the prevalence of eye disease, and the spike in demand for medications to treat optic nerve disorders all point to high promise in unexplored, emerging markets. Additionally, the desire for better healthcare services, large government investments in enhancing the infrastructure for healthcare, and the growth of the medical tourism sector in emerging nations are all contributing to the significant growth of the healthcare sector in emerging economies.
Optic Nerve Disorders Treatment Market, By Geography
North America
Europe
Asia Pacific
Middle East and Africa
Latin America
Based on Geography, The Global Optic Nerve Disorders Treatment Market is classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. Due to its high illness prevalence, accessibility of reimbursement policies, and rising public awareness of multiple sclerosis and optic neuritis, the Asia Pacific area is anticipated to rise more than any other region throughout the forecasted period.
The market has grown in this area due to the presence of pharmaceutical companies there as well as the increasing purchasing power of populous countries like China and India. The market is expanding due to the aging population as well as the rising prevalence of diseases affecting the optic nerve, including glaucoma and optic neuritis.
Key Players
The "Global Optic Nerve Disorders Treatment Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as Bionure Farma S.L., Teva Pharmaceutical Industries Ltd, Santen Pharmaceutical Co. Ltd., Novartis AG, Pfizer Inc., Allergan plc., Aerie Pharmaceuticals Inc, Mallinckrodt Pharmaceuticals, Merck Sharp & Dohme Corp, and Bausch Health Companies, Inc.
Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.
Key Developments
In February 2022, The results of a recent trial conducted by Horizon Therapeutics plc (Nasdaq: HZNP) showed that UPLIZNA medication effectively reduced the intensity of attacks in NMOSD patients.
Ace Matrix Analysis
The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.
Market Attractiveness
The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Global Optic Nerve Disorders Treatment Market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.
Porter's Five Forces
The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. The porter's five forces model can be used to assess the competitive landscape in Global Optic Nerve Disorders Treatment Market gauge the attractiveness of a certain sector, and assess investment possibilities.
TABLE OF CONTENTS
1 INTRODUCTION OF GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions
2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH
2.1 Data mining
2.2 Secondary research
2.3 Primary research
2.4 Subject matter expert advice
2.5 Quality check
2.6 Final review
2.7 Data triangulation
2.8 Bottom-up approach
2.9 Top-down approach
2.10 Research flow
2.11 Data sources
3 EXECUTIVE SUMMARY
3.1 Overview
3.2 Absolute $ Opportunity
3.3 Market attractiveness
3.4 Future Market Opportunities
4 GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET OUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET, BY TYPE OF TREATMENT
5.1 Overview
5.2 Eye Drops
5.3 Steroids
5.4 Intravenous immune Globulin/ Plasma Exchange
5.5 Vitamin B12 injection
5.6 Surgery
6 GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET, BY TYPE OF NREVE DISORDER
6.1 Overview
6.2 Glaucoma
6.3 Optic neuritis
6.4 Others
7 GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET, BY END USER
7.1 Overview
7.2 Hospitals
7.3 Ophthalmology Clinics
7.4 Ambulatory Surgical Centers
8 GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET, BY GEOGRAPHY
8.1 Overview
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.2.3 Mexico
8.3 Europe
8.3.1 Germany
8.3.2 U.K.
8.3.3 France
8.3.4 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Rest of Asia Pacific
8.5 Rest of the World
8.5.1 Latin America
8.5.2 Middle East and Africa
9 GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET COMPETITIVE LANDSCAPE
